PMID- 33751787
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 41
IP  - 6
DP  - 2021 Jun
TI  - Safety of fibrates in cholestatic liver diseases.
PG  - 1335-1343
LID - 10.1111/liv.14871 [doi]
AB  - BACKGROUND AND AIM: Off-label use of fibrates in patients with cholestatic liver 
      diseases results in improved biochemical parameters and pruritus; however, their 
      safety in this population has been a concern. This study summarizes safety data 
      for fibrates when used for treatment of cholestatic liver diseases. METHODS: A 
      systematic review of published studies evaluating the use of fibrates for 
      treatment of primary biliary cholangitis (PBC) and primary sclerosing cholangitis 
      (PSC) was performed. Electronic databases were searched up to December 2019 for 
      published studies evaluating treatment outcomes associated to fibrates for these 
      2 diseases. RESULTS: A total of 37 studies were identified, including 31 for PBC 
      and 6 for PSC, with a total of 1107 unique patients treated with 
      fibrates +/- ursodeoxycholic acid (UDCA). Most studies evaluated fenofibrate and 
      bezafibrate, and only 1 study evaluated pemafibrate. There were no studies 
      evaluating gemfibrozil or clofibrate. The most commonly reported adverse events 
      (AEs) were gastrointestinal and musculoskeletal. Elevations of aminotransferases 
      and serum creatinine were reported more commonly in patients treated with UDCA 
      plus fibrates versus UDCA monotherapy. CONCLUSIONS: Fibrates appear to be safe 
      and well tolerated in patients with PBC, with a low frequency of AEs. There are 
      scarce data about the safety of these agents for treatment of PSC.
CI  - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Carrion, Andres F
AU  - Carrion AF
AUID- ORCID: 0000-0001-5805-6638
AD  - Division of Gastroenterology and Hepatology, University of Miami, Miami, FL, USA.
FAU - Lindor, Keith D
AU  - Lindor KD
AUID- ORCID: 0000-0003-1046-5621
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.
AD  - Office of University Provost, Arizona State University, Phoenix, AZ, USA.
FAU - Levy, Cynthia
AU  - Levy C
AUID- ORCID: 0000-0001-5498-6037
AD  - Division of Gastroenterology and Hepatology, University of Miami, Miami, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20210318
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Cholagogues and Choleretics)
RN  - 0 (Fibric Acids)
RN  - 724L30Y2QR (Ursodeoxycholic Acid)
RN  - Y9449Q51XH (Bezafibrate)
SB  - IM
MH  - Bezafibrate/adverse effects
MH  - *Cholagogues and Choleretics/adverse effects
MH  - Fibric Acids/adverse effects
MH  - Humans
MH  - *Liver Cirrhosis, Biliary/drug therapy
MH  - Ursodeoxycholic Acid/adverse effects
OTO - NOTNLM
OT  - bezafibrate
OT  - fenofibrate
OT  - fibrates
OT  - primary biliary cholangitis
OT  - primary sclerosing cholangitis
EDAT- 2021/03/23 06:00
MHDA- 2021/06/29 06:00
CRDT- 2021/03/22 19:39
PHST- 2021/02/11 00:00 [revised]
PHST- 2020/09/10 00:00 [received]
PHST- 2021/03/01 00:00 [accepted]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2021/03/22 19:39 [entrez]
AID - 10.1111/liv.14871 [doi]
PST - ppublish
SO  - Liver Int. 2021 Jun;41(6):1335-1343. doi: 10.1111/liv.14871. Epub 2021 Mar 18.